Skip to Main Content

Author Details

Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
2000
332
157
PMIDPaper TitleJournal TitlePublished Year
37823831Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.Cancer Discov2024
37823831Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.Cancer Discov2024
37916958Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.Cancer Discov2024
37916958Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.Cancer Discov2024
36287227Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Blood Adv2023
36240479Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.J Clin Oncol2023
36287227Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.Blood Adv2023
35358998The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.Blood Adv2023
37938768Latent human herpesvirus 6 is reactivated in CAR T cells.Nature2023
38019104Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.Cancer Res Commun2023
37738974ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.Cancer Cell2023
37653227Author Correction: Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling.Nat Biotechnol2023
37808694Germline mutations and developmental mosaicism underlying <i>EGFR</i>-mutant lung cancer.medRxiv2023
37577538Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.bioRxiv2023
37794034Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.Nat Commun2023
37474833Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.Nat Cancer2023
37407818Therapy-induced APOBEC3A drives evolution of persistent cancer cells.Nature2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37146250Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.Blood2023
37081260Inferring early genetic progression in cancers with unobtainable premalignant disease.Nat Cancer2023
36821441TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state.Cell Rep2023
36702949Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trial.Nat Med2023
36697832Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.Nature2023
36697836Author Correction: The repertoire of mutational signatures in human cancer.Nature2023
37126021Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Clin Cancer Res2023
36624313Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.Nat Med2023
36477267MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology.Cancer Discov2023
37053197Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.Clin Cancer Res2023
36468984In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.Blood Cancer Discov2023
37535729<i>CXCL9:SPP1</i> macrophage polarity identifies a network of cellular programs that control human cancers.Science2023
37505099IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.Blood Adv2023
37808694Germline mutations and developmental mosaicism underlying <i>EGFR</i>-mutant lung cancer.medRxiv2023
38019104Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma.Cancer Res Commun2023
37794034Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.Nat Commun2023
37653227Author Correction: Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling.Nat Biotechnol2023
37505099IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.Blood Adv2023
37738974ZNF683 marks a CD8<sup>+</sup> T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome.Cancer Cell2023
37938768Latent human herpesvirus 6 is reactivated in CAR T cells.Nature2023
37577538Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.bioRxiv2023
37535729<i>CXCL9:SPP1</i> macrophage polarity identifies a network of cellular programs that control human cancers.Science2023
35358998The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.Blood Adv2023
37126021Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Clin Cancer Res2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37053197Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.Clin Cancer Res2023
37081260Inferring early genetic progression in cancers with unobtainable premalignant disease.Nat Cancer2023
37146250Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.Blood2023
37407818Therapy-induced APOBEC3A drives evolution of persistent cancer cells.Nature2023
37474833Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.Nat Cancer2023
36697832Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.Nature2023
36697836Author Correction: The repertoire of mutational signatures in human cancer.Nature2023
  • 1 - 50 of 664

Recommended Authors

Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 13
Daniel H??bschmann
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Career Start Year 2016
Number of shared co-authors 32
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 36
Daniel Vod??k
Institute for Cancer Research, Oslo University Hospital
Career Start Year 2014
Number of shared co-authors 20
Jiguang Wang
The Hong Kong University of Science and Technology
Career Start Year 2012
Number of shared co-authors 25
Timothy Beck
Human Longevity Inc.
Career Start Year 2012
Number of shared co-authors 25
Richard de Borja
The Hospital for Sick Children
Career Start Year 2012
Number of shared co-authors 32
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 24
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 35
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 15
Moritz Gerstung
German Cancer Research Centre DKFZ
Career Start Year 2007
Number of shared co-authors 22
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 53
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 51
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 19
David Jones
Wellcome Sanger Institute
Career Start Year 2005
Number of shared co-authors 42
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 22
Keiran Raine
Wellcome Sanger Institute
Career Start Year 2004
Number of shared co-authors 48
Matthias Schlesner
University of Augsburg
Career Start Year 2004
Number of shared co-authors 59
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 11
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 72
Malachi Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 82
Peter Van Loo
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 47
Sohrab P Shah
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 53
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 33
Serena Nik-Zainal
Early Cancer Institute, University of Cambridge
Career Start Year 1999
Number of shared co-authors 28
Adam Butler
Wellcome Sanger Institute
Career Start Year 1996
Number of shared co-authors 65
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year 1996
Number of shared co-authors 54
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 22
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 107

Collaborators

Matthew Meyerson
Broad Institute
Co-authored papers 85
Michael S Lawrence
Co-authored papers 84
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 64
Chip Stewart
Broad Institute of MIT and Harvard
Co-authored papers 57
Eric S Lander
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 55
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 54
Scott L Carter
Co-authored papers 53
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 50
Jaegil Kim
Co-authored papers 49
Kristian Cibulskis
Co-authored papers 49
Carrie Sougnez
The Broad Institute of Harvard and MIT
Co-authored papers 43
Catherine J Wu
Co-authored papers 40
Rameen Beroukhim
Co-authored papers 40
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 37
Amaro Taylor-Weiner
Co-authored papers 36
Ignaty Leshchiner
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 35
Donna Neuberg
Co-authored papers 33
Mara Rosenberg
Broad Institute of MIT and Harvard
Co-authored papers 28
Andrey Sivachenko
Cystic Fibrosis Foundation
Co-authored papers 27
Aaron McKenna
Co-authored papers 27
Gordon Saksena
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 26
Petar Stojanov
Co-authored papers 25
Nir Hacohen
Broad Institute of MIT and Harvard
Co-authored papers 23
Wendy Winckler
Co-authored papers 23
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 22
Nicholas J Haradhvala
Co-authored papers 22
Daniel Auclair
Co-authored papers 21
Julian M Hess
Broad Institute of MIT and Harvard
Co-authored papers 20
Dimitri Livitz
Co-authored papers 20
François Aguet
Co-authored papers 19
Release 1.2